Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo
Public ClinicalTrials.gov record NCT02505542. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondyloarthritis (axSpA) Receiving Either Certolizumab Pegol 200 mg Q2W or 200 mg Q4W as Compared to Placebo
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Patients receive study drug for one year (Part A). If, after the initial run-in phase, a sustained remission is reached they will be randomly split into one of three dose groups for another year (Part B). The maintenance of the sustained remission will be analyzed.
Study identification
- NCT ID
- NCT02505542
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 736 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 45 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2015 (Actual)
- Primary completion
- Feb 2019 (Actual)
- Completion
- Apr 2019 (Actual)
- Last update posted
- Dec 17, 2020
2015 – 2019
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| As0005 2313 | Glendale | Arizona | 85304 | — |
| As0005 2316 | Mesa | Arizona | 85202 | — |
| As0005 2314 | Phoenix | Arizona | 85037 | — |
| As0005 2317 | Sun City | Arizona | 85351 | — |
| As0005 2307 | Palm Desert | California | 92260 | — |
| As0005 2310 | San Francisco | California | 94143 | — |
| As0005 2305 | Upland | California | 91786 | — |
| As0005 2308 | Denver | Colorado | 80230 | — |
| As0005 2302 | Brandon | Florida | 33511 | — |
| As0005 2321 | Hagerstown | Maryland | 21742 | — |
| As0005 2312 | Minot | North Dakota | 58701 | — |
| As0005 2323 | Oklahoma City | Oklahoma | 73101 | — |
| As0005 2311 | Duncansville | Pennsylvania | 16635 | — |
| As0005 2315 | Jackson | Tennessee | 38305 | — |
| As0005 2303 | Austin | Texas | 78731 | — |
| As0005 2318 | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 92 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02505542, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2020 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02505542 live on ClinicalTrials.gov.